drugset / Trial / NCT03420014
Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
RandomizedParallel-groupOpen-labelTreatment
Summary
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.
Timeline
- Start
- 2018-12-27
- Primary completion
- 2024-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Comparator | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Onfekafusp alfa | Protein / enzyme biologic | 13 ug/kg | Intravenous |